HL40626S / HighsLab Therapeutics - LARVOL DELTA

HL4134, a potential Best-in-Class Oral Cyclic Peptide Targeting IL-23 Receptor with Potential comparable Efficacy for Psoriasis Treatment, Compared to Leading Anti-IL-23 P19 Monoclonal Antibodies (EADV 2026) - "HL4134 is predicted to achieve skin tissue exposure levels relative to IC50 that are comparable or superior to anti-IL-23 monoclonal antibodies (risankizumab and guselkumab). These data suggest that HL4134 may demonstrate efficacy in psoriasis treatment equivalent or superior to existing monoclonal antibody therapies while offering the convenience of oral administration."

Clinical • Dermatology • Immunology • Psoriasis • IFNG • IL17A • IL22 • IL23A • S100A8 • S100A9